Top ten stories in the pharmaceutical industry this week
pharmafile | August 26, 2016 | News story | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | pharmafile, top 10
If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians taking aim yet again at the industry to send stocks falling, and Pfizer again on the acquisition trail, there was plenty to dissect in pharma over the last seven days. Here are the ten most popular articles on Pharmafile this week.
10. FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due
The regulator is demanding more information on the drug delivery service for iGlarLixi
9. Doctors receiving drugmaker payments more likely to prescribe their products, BMJ study finds
Study links payments and gifts to US doctors to higher prescriptions of branded anticoagulants and diabetes drugs
8. Positive Phase III results for Novartis MS drug
Secondary progressive multiple sclerosis treatment meets primary endpoints in the largest MS trial to date
7. MHRA suspends GMP certificate for Pfizer site in India
The UK’s Medicines and Healthcare products Regulatory Agency heavily criticised the site for issues such as “poorly designed autoclave load patterns” and other sterilisation issues
6. AbbVie’s leukaemia drug granted positive opinion by MHRA through EAMS
Venetoclax becomes the first blood cancer drug to be made available through the Early Access to Medicines Scheme
5. The impact of Brexit on the pharmaceutical industry: some preliminary considerations
It may be hard to believe it’s only been two months since the historic vote, and many readers are still keen to learn how Brexit will impact the pharmaceutical industry – whenever Article 50 eventually gets triggered, that is.
4. Teva loses patent protection on lucrative MS treatment
Copaxone (glatiramer acetate) accounts for around 20% of the company’s revenue
3. Mylan latest target of US anger on drug pricing with EpiPen price increase
CEO Heather Bresch has received a salary increase of 671% while the cost of EpiPen has risen 400%
2. FDA approves Pfizer’s abuse-deterrent opioid painkiller
Troxyca ER becomes the only oxycodone with oral abuse-deterrent features described in the labelling
1. Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront
Potential milestone payments could make the deal worth up to $1.5 billion
Related Content
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s top 10 news stories of the week
COVID-19 news has slowed down in the last week, allowing different pharma developments to take …
Pharmafile.com’s top 10 news stories of the week
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …
